Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | GFER | P55789 | 1/20 | 0.43 |
| ▸ | COPS5 | Q92905 | 2/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
| ▸ | METAP1 | P53582 | 1/20 | 0.42 |
| ▸ | PSMD14 | O00487 | 2/20 | 0.41 |
| ▸ | NQO2 | P16083 | 1/20 | 0.41 |
| ▸ | STK17B | O94768 | 1/20 | 0.41 |
| ▸ | STK17A | Q9UEE5 | 1/20 | 0.41 |
| ▸ | STAMBP | O95630 | 1/20 | 0.41 |
| ▸ | CA12 | O43570 | 1/20 | 0.40 |
| ▸ | CA1 | P00915 | 1/20 | 0.40 |
| ▸ | CA2 | P00918 | 1/20 | 0.40 |
| ▸ | CA9 | Q16790 | 1/20 | 0.40 |
| ▸ | NAMPT | P43490 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28231828 | 0.92 | L3MBTL1 (0.51) | L3MBTL1HTTTDP1METAP1STK17B | |
| SCHEMBL4035435 | 0.90 | L3MBTL1 (0.50) | L3MBTL1HTTTDP1STK17BSTK17A | |
| SCHEMBL1585659 | 0.85 | L3MBTL1 (0.47) | L3MBTL1ALDH1A1METAP1NAMPT | |
| SCHEMBL21743808 | 0.83 | L3MBTL1 (0.51) | L3MBTL1TDP1STK17BSTK17ACA12 | |
| SCHEMBL3564269 | 0.83 | L3MBTL1 (0.48) | L3MBTL1TDP1METAP1STK17BSTK17A | |
| SCHEMBL16133682 | 0.81 | COPS5 (0.45) | L3MBTL1HTTNPSR1ALDH1A1COPS5 | |
| SCHEMBL8041384 | 0.80 | L3MBTL1 (0.43) | L3MBTL1ALDH1A1METAP1MEN1KMT2A | |
| SCHEMBL31421303 | 0.79 | L3MBTL1 (0.54) | L3MBTL1HTTNPSR1ALDH1A1TDP1 | |
| SCHEMBL4696490 | 0.79 | HTT (0.43) | HTTNPSR1ALDH1A1GFERTDP1 | |
| SCHEMBL7628177 | 0.79 | COPS5 (0.48) | L3MBTL1ALDH1A1COPS5PSMD14STAMBP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10703754-B2 | Compounds and compositions for treating chemical warfare agent-induced injuries | ELI LILLY AND COMPANY (US) | 2020-07-07 | — | — | US | disclosed |
| EP-3663295-A1 | 2,6-DIOXO,-2,3-DIHYDRO-1H-PURINE COMPOUNDS USEFUL FOR TREATING DISORDERS RELATED TO THE ACTIVITY OF THE TRPA1 CHANNEL | ELI LILLY AND CO. (US) | 2020-06-10 | — | — | EP | disclosed |
| EP-3184527-B1 | 2,6-DIOXO,-2,3-DIHYDRO-1H-PURINE COMPOUNDS USEFUL FOR TREATING DISORDERS RELATED TO THE ACTIVITY OF THE TRPA1 CHANNEL | LILLY CO ELI (US) | 2020-01-29 | — | — | EP | disclosed |
| US-20190194202-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CHEMICAL WARFARE AGENT-INDUCED INJURIES | ELI LILLY AND COMPANY | 2019-06-27 | — | — | US | disclosed |
| CN-108290878-A | NOVEL FERROPORTIN INHIBITORS | 威佛（国际）股份公司 | 2018-07-17 | — | — | CN | disclosed |
| US-20180133170-A1 | METHODS AND COMPOSITIONS FOR TREATING DISORDERS | ELI LILLY AND COMPANY | 2018-05-17 | — | — | US | disclosed |
| US-9951073-B2 | Compounds and compositions for treating chemical warfare agent-induced injuries | HYDRA BIOSCIENCES, INC. (US) | 2018-04-24 | — | — | US | disclosed |
| EP-3184527-A1 | 2,6-DIOXO,-2,3-DIHYDRO-1H-PURINE COMPOUNDS USEFUL FOR TREATING DISORDERS RELATED TO THE ACTIVITY OF THE TRPA1 CHANNEL | Hydra Biosciences, Inc. (US) | 2017-06-28 | — | — | EP | disclosed |
| EP-2170309-B1 | 2,6-DIOXO,-2,3-DIHYDRO-1H-PURINE COMPOUNDS USEFUL FOR TREATING DISORDERS RELATED TO THE ACTIVITY OF THE TRPA1 CHANNEL | HYDRA BIOSCIENCES INC (US) | 2016-10-26 | — | — | EP | disclosed |
| US-20130303521-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CHEMICAL WARFARE AGENT-INDUCED INJURIES | HYDRA BIOSCIENCES, INC (US) | 2013-11-14 | — | — | US | disclosed |
| US-8163761-B2 | Methods and compositions for treating disorders | HYDRA BIOSCIENCES, INC. (US) | 2012-04-24 | — | — | US | disclosed |
| US-20120046305-A1 | METHODS AND COMPOSITIONS FOR TREATING RESPIRATORY DISORDERS | ELI LILLY AND COMPANY | 2012-02-23 | — | — | US | disclosed |
| EP-2211862-A2 | CSF-1R INHIBITORS FOR TREATMENT OF CANCER AND BONE DISEASES | Novartis AG (CH) | 2010-08-04 | — | — | EP | disclosed |
| WO-2010036821-A1 | METHODS AND COMPOSITIONS FOR TREATING RESPIRATORY DISORDERS | HYDRA BIOSCIENCES, INC. (US) | 2010-04-01 | — | — | WO | disclosed |
| WO-2009140517-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CHEMICAL WARFARE AGENT-INDUCED INJURIES | HYDRA BIOSCIENCES, INC. (US) | 2009-11-19 | — | — | WO | disclosed |
| US-20090143377-A1 | METHODS AND COMPOSITIONS FOR TREATING DISORDERS | ELI LILLY AND COMPANY | 2009-06-04 | — | — | US | disclosed |
| US-20090143377-A1 | METHODS AND COMPOSITIONS FOR TREATING DISORDERS | ELI LILLY AND COMPANY | 2009-06-04 | — | — | US | disclosed |
| WO-2009050228-A2 | CSF-1R INHIBITORS FOR TREATMENT OF CANCER AND BONE DISEASES | NOVARTIS AG (CH) | 2009-04-23 | — | — | WO | disclosed |
| WO-2009002933-A1 | METHODS AND COMPOSITIONS FOR TREATING DISORDERS | HYDRA BIOSCIENCES, INC. (US) | 2008-12-31 | — | — | WO | disclosed |
| WO-2005028454-A1 | HALOALKYL CONTAINING COMPOUNDS AS CYSTEINE PROTEASE INHIBITORS | AXYS PHARMACEUTICALS, INC. (US) | 2005-03-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10703754-B2 | Compounds and compositions for treating chemical warfare agent-induced injuries | ELANE, CASP3, MMP8 | L3MBTL1 1305/4885HTT 4377/4885NPSR1 1396/4885 |
| US-20180133170-A1 | METHODS AND COMPOSITIONS FOR TREATING DISORDERS | TRPA1, TRPV1, TRPV3 | L3MBTL1 3959/4885HTT 160/4885NPSR1 325/4885 |
| US-20090143377-A1 | METHODS AND COMPOSITIONS FOR TREATING DISORDERS | TRPA1, TRPV1, TRPV3 | L3MBTL1 3959/4885HTT 160/4885NPSR1 325/4885 |
| US-20120046305-A1 | METHODS AND COMPOSITIONS FOR TREATING RESPIRATORY DISORDERS | TRPA1, TRPV1, TRPV3 | L3MBTL1 3252/4885HTT 1239/4885NPSR1 685/4885 |
| US-20130303521-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CHEMICAL WARFARE AGENT-INDUCED INJURIES | ELANE, CASP3, MMP8 | L3MBTL1 1305/4885HTT 4377/4885NPSR1 1396/4885 |
| US-20190194202-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CHEMICAL WARFARE AGENT-INDUCED INJURIES | ELANE, CASP3, MMP8 | L3MBTL1 1305/4885HTT 4377/4885NPSR1 1396/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.